WASHINGTON, D.C., Feb. 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM) today announced the release of its 2018 Annual Data Report, offering an in-depth look at trends and metrics for the cell therapy, gene therapy, tissue engineering, and broader global regenerative medicine sector.
Using data provided by ARM’s data partner Informa, curated and further analyzed by ARM’s staff, the report details industry-specific statistics and trends from more than 900 leading cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide. Key features of the report include total financings for the sector, partnerships and other deals, clinical trial information, major clinical data events, current legislative and regulatory priorities, and expert commentary from industry representatives in the U.S. and Europe.
Key findings from the 2018 annual report include:
- Globally, companies active in gene and cell therapies and other regenerative medicines raised more than $13.3 billion in 2018, a 73% increase over 2017. The report also includes data broken out by technology and financing type.
- There were 1,028 clinical trials underway worldwide by year-end 2018. The report includes figures on clinical trials by phase, technology type, and indication.
- In Europe, the sector raised $2.2B (approximately €1.7B) in 2018, an increase of 40% over 2017, and 216 clinical trials were ongoing by year-end 2018.
- Industry experts expressed optimism about the future of the sector, but emphasized the need to address issues with manufacturing and scale-up as these therapies come to market, as well as the need to think creatively about financing and payment models.
“We’re seeing tremendous growth in this field. 2018 financings surpassed even 2015, which was a watershed year in terms of investment for the sector,” said Janet Lambert, CEO of ARM. “But even more exciting is seeing the increasing number of patients able to access these truly transformative therapies, when before they didn’t have many, if any, options for treatment. We’re excited to see that trend continue in 2019, with additional approvals expected in the U.S. and abroad.”
“ATMPs hold enormous potential value for patients, healthcare systems, and society,” said Annie Hubert, Senior Director of European Public Policy at ARM, in an overview of the European ATMP landscape included in the report. “As we go forward, ARM will continue to engage stakeholders in Europe and globally to build a supportive infrastructure for these therapies, and to ensure patients in Europe are able to access safe and effective products.”
ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers, and clinical data events.
The report is available to download here, with interactive data and downloadable infographics available here. Past reports, issued quarterly and annually, are available here.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 300 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.